Alternatived Products of [ 50675-23-5 ]
Product Details of [ 50675-23-5 ]
CAS No. : | 50675-23-5 |
MDL No. : | MFCD11054023 |
Formula : |
C8H16O2
|
Boiling Point : |
- |
Linear Structure Formula : | - |
InChI Key : | - |
M.W : |
144.21
|
Pubchem ID : | - |
Synonyms : |
|
Application In Synthesis of [ 50675-23-5 ]
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
- Downstream synthetic route of [ 50675-23-5 ]
- 1
-
[ 50675-23-5 ]
-
[ 50675-25-7 ]
Yield | Reaction Conditions | Operation in experiment |
|
Multi-step reaction with 2 steps
1: dmap; pyridine / dichloromethane / 18 h / 20 °C
2: ammonia / tetrahydrofuran / -78 - 125 °C |
|
|
Multi-step reaction with 2 steps
1: dmap; pyridine / dichloromethane / 18 h / 20 °C
2: ammonia / tetrahydrofuran / 18 h / -78 - 125 °C |
|
|
Multi-step reaction with 2 steps
1: dmap; pyridine / dichloromethane / 18 h / 20 °C
2: ammonia / tetrahydrofuran / 18 h / -78 - 125 °C / Autoclave |
|
|
Multi-step reaction with 2 steps
1: dmap; triethylamine / dichloromethane / 18 h / 20 °C
2: ammonia / tetrahydrofuran / 18 h / 125 °C |
|
|
Multi-step reaction with 2 steps
1: pyridine / dmap / dichloromethane / 18 h / 20 °C
2: ammonia / tetrahydrofuran / 18 h / -78 - 125 °C |
|
|
Multi-step reaction with 2 steps
1: dmap; pyridine / dichloromethane / 18 h / 20 °C
2: ammonia / tetrahydrofuran / 18 h / 125 °C |
|
|
Multi-step reaction with 2 steps
1: pyridine; dmap / dichloromethane / 18 h / 20 °C
2: ammonia / tetrahydrofuran / 18 h / -78 - 125 °C |
|
|
Multi-step reaction with 2 steps
1: pyridine; dmap / dichloromethane / 18 h / 20 °C
2: ammonia / tetrahydrofuran / 18 h / 125 °C / steel bomb |
|
Reference:
[1]Current Patent Assignee: NOVARTIS AG; Novartis (w/o Sandoz) - WO2011/26904, 2011, A1
[2]Current Patent Assignee: Novartis (w/o Sandoz); NOVARTIS AG - WO2012/66065, 2012, A1
[3]Current Patent Assignee: Novartis (w/o Sandoz); NOVARTIS AG - WO2012/66070, 2012, A1
[4]Current Patent Assignee: Novartis (w/o Sandoz); NOVARTIS AG - WO2012/101063, 2012, A1
[5]Current Patent Assignee: NOVARTIS AG; Novartis (w/o Sandoz) - WO2012/101066, 2012, A1
[6]Current Patent Assignee: Novartis (w/o Sandoz); NOVARTIS AG - WO2012/101064, 2012, A1
[7]Current Patent Assignee: NOVARTIS AG; Novartis (w/o Sandoz) - WO2011/26917, 2011, A1
[8]Current Patent Assignee: NOVARTIS AG; Novartis (w/o Sandoz) - WO2012/101065, 2012, A2
- 2
-
[ 52916-16-2 ]
-
[ 50675-23-5 ]
Yield | Reaction Conditions | Operation in experiment |
|
With borane-THF; In tetrahydrofuran; at 0℃; for 2h; |
Intermediate 071 (2,2-Dimethyltetrahydro-2H-pyran-4-yl)methanol <strong>[52916-16-2]2,2-Dimethyltetrahydro-2H-pyran-4-carboxylic acid</strong> (820 mg, 5.18 mmol) was dissolved in tetrahydrofuran (16 mL). At 0 C BH3-tetrahydrofuran-complex (668 mg, 7.78 mmol) was added and stirred for another 2 hours at 0 C. It was quenched with saturated ammonium chloride solution, the organic solvent was removed in vacuo, water was added and it was extracted twice with ethyl acetate. The combined organic phases were dried over sodium sulfate and concentrated in vacuo. As GC-MS showed only 50% conversion the same procedure was repeated leading to crude (2,2-dimethyltetrahydro-2H-pyran-4-yl)methanol (491 mg) which was used in the next step without further purification. |